S1P lyase regulates DNA damage responses through a novel sphingolipid feedback mechanism
Open Access
- 10 February 2011
- journal article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 2 (2), e119
- https://doi.org/10.1038/cddis.2011.3
Abstract
The injurious consequences of ionizing radiation (IR) to normal human cells and the acquired radioresistance of cancer cells represent limitations to cancer radiotherapy. IR induces DNA damage response pathways that orchestrate cell cycle arrest, DNA repair or apoptosis such that irradiated cells are either repaired or eliminated. Concomitantly and independent of DNA damage, IR activates acid sphingomyelinase (ASMase), which generates ceramide, thereby promoting radiation-induced apoptosis. However, ceramide can also be metabolized to sphingosine-1-phosphate (S1P), which acts paradoxically as a radioprotectant. Thus, sphingolipid metabolism represents a radiosensitivity pivot point, a notion supported by genetic evidence in IR-resistant cancer cells. S1P lyase (SPL) catalyzes the irreversible degradation of S1P in the final step of sphingolipid metabolism. We show that SPL modulates the kinetics of DNA repair, speed of recovery from G2 cell cycle arrest and the extent of apoptosis after IR. SPL acts through a novel feedback mechanism that amplifies stress-induced ceramide accumulation, and downregulation/inhibition of either SPL or ASMase prevents premature cell cycle progression and mitotic death. Further, oral administration of an SPL inhibitor to mice prolonged their survival after exposure to a lethal dose of total body IR. Our findings reveal SPL to be a regulator of ASMase, the G2 checkpoint and DNA repair and a novel target for radioprotection.Keywords
This publication has 37 references indexed in Scilit:
- New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cellsEuropean Journal of Pharmacology, 2009
- Acid sphingomyelinase, cell membranes and human disease: Lessons from Niemann–Pick diseaseFEBS Letters, 2009
- Lyase to live by: Sphingosine phosphate lyase as a therapeutic targetEmerging Therapeutic Targets, 2009
- Fine Tuning the Cell Cycle: Activation of the Cdk1 Inhibitory Phosphorylation Pathway during Mitotic ExitMolecular Biology of the Cell, 2009
- Incomplete Inhibition of Sphingosine 1-Phosphate Lyase Modulates Immune System Function yet Prevents Early Lethality and Non-Lymphoid LesionsPLOS ONE, 2009
- Activation of Sphingosine Kinase-1 Reverses the Increase in Lung Vascular Permeability Through Sphingosine-1-Phosphate Receptor Signaling in Endothelial CellsCirculation Research, 2008
- Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancerProceedings of the National Academy of Sciences of the United States of America, 2006
- Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: Implications for endothelial apoptosisCancer Biology & Therapy, 2005
- Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastropheCell Death & Differentiation, 2002
- Ceramide Mediates the Apoptotic Response of WEHI 231 Cells to Anti-immunoglobulin, Corticosteroids and IrradiationBiochemical and Biophysical Research Communications, 1994